DOCSLIB.ORG

Hmob3 Modulates MST1 Apoptotic Signaling and Supports Tumor Growth In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hmob3 Modulates MST1 Apoptotic Signaling and Supports Tumor Growth In Author Manuscript Published OnlineFirst on May 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3430 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 hMOB3 modulates MST1 apoptotic signaling and supports tumor growth in 2 glioblastoma multiforme 3 Fengyuan Tang1*, Lei Zhang1, Gongda Xue1, Debby Hynx1, Yuhua Wang1, Peter D. Cron1, 4 Christian Hundsrucker1,4, Alexander Hergovich3, Stephan Frank2, Brian A. Hemmings1, Debora 5 Schmitz-Rohmer1* 6 1 Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland ; 2 Division of 7 Neuropathology, Institute of Pathology, University of Basel, Switzerland; 3 Cancer Institute 8 University College London, London, UK; 4 Swiss Institute of Bioinformatics, Basel, Switzerland 9 Running Title: hMOB3 inhibits apoptotic MST1 cleavage and promotes tumor growth 10 Keywords: apoptosis, etoposide, proliferation, STK4, caspase cleavage 11 Financial Support: Gongda Xue and Debora Schmitz-Rohmer are supported by the Swiss 12 National Science Foundation SNF 31003A_130838 and 31003A_138287, respectively. Christian 13 Hundsrucker is supported by Swiss Initiative in Systems Biology (Systems Biology IT). 14 Alexander Hergovich is a Wellcome Trust Research Career Development fellow (grant 15 090090/Z/09/Z). The FMI is supported by the Norvartis Research Foundation. 16 *Corresponding authors. Mailing address: Friedrich Miescher Institute for Biomedical 17 Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland. E-mail: [email protected] and 18 [email protected] . Phone: +41-61-6974872 or +41-61-6974046; Fax: +41-61-6973976; 19 Conflict of interest: The authors disclose no potential conflicts of interest. 20 Word count: 5263 words 6 Figures +3 Supplemental Figures 1 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3430 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 21 Abstract: 22 New therapeutic targets are needed that circumvent inherent therapeutic resistance of 23 glioblastoma multiforme (GBM). Here we report such a candidate target in the uncharacterized 24 adaptor protein hMOB3, which we show is upregulated in GBM. In a search for its biochemical 25 function, we found that hMOB3 specifically interacts with MST1 kinase in response to apoptotic 26 stimuli and cell-cell contact. Moreover, hMOB3 negatively regulated apoptotic signaling by 27 MST1 in GBM cells by inhibiting the MST1 cleavage-based activation process. Physical 28 interaction between hMOB3 and MST1 was essential for this process. In vivo investigations 29 established that hMOB3 sustains GBM cell growth at high cell density and promotes 30 tumorigenesis. Our results suggest hMOB3 as a candidate therapeutic target for the treatment of 31 malignant gliomas. 32 33 34 35 36 37 38 39 40 2 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3430 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 41 Introduction 42 Glioblastoma multiforme (GBM) is the most common and aggressive primary human brain 43 tumor, with a median survival of approximately 14 months after diagnosis. Despite the benefits 44 of surgical resection and the use of adjuvant radiochemotherapies, patients almost invariably 45 succumb to recurrent widespread tumor growth (1, 2). Thus, defining the mechanism of 46 resistance of GBM cells and discovering further effective therapeutic targets are crucial medical 47 goals. 48 The Hippo pathway is an evolutionarily conserved tumor suppressive signal originally identified 49 in Drosophila as a tumor suppressive signal (3-9). Deregulation of Hippo signaling components, 50 such as MST and LATS/NDR kinases, MOB1 proteins, as well as the downstream effector YAP, 51 has been reported in numerous animal tumor models and human malignancies (10). 52 MST1 (Sterile 20-like kinase 1), the mammalian homolog of the Hippo kinase, plays a critical 53 role in regulating cellular apoptosis and proliferation (11-15). MST1 contains an N-terminal 54 kinase domain, followed by an auto-inhibitory domain and a C-terminal protein-protein 55 interaction domain called SARAH (Salvador-RASSF-Hippo) (16). In response to apoptotic 56 stimuli, MST1 is activated by dimerization-mediated trans-phosphorylation and caspase- 57 mediated cleavage (17-20). Cleaved MST1 translocates from the cytoplasm into the nucleus and 58 induces chromatin condensation by phosphorylation different targets (21-25). Although Akt and 59 JNK have been reported to phosphorylate MST1 and modulate its cleavage (26-29), the 60 regulation of apoptotic MST1 signaling has not been completely defined. 61 MOB1 (Mps One Binder 1) proteins were first characterized in yeast, where they are essential 62 components of mitotic exit and septation initiation networks (30, 31). Drosophila mob1/mats 3 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3430 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 63 functions as a tumor suppressor by regulating the activation of the Warts kinase (32, 33). The 64 mammalian genome encodes 6 MOB proteins through 6 different genes, namely MOB1A/B, 65 MOB2 and MOB3A/B/C (34, 35). Mammalian Mob1A and Mob1B are essential for embryonic 66 development and prevent tumorigenesis in a broad range of tissues via a mechanism similar to 67 that reported in flies (36, 37). The function of human MOB1 has been characterized as a co- 68 activator of the MST-NDR/LATS kinase cascade (38, 39). Human MOB2 has been reported to 69 restrict NDR kinase signaling (34). Although hMOB3 shares higher amino acid sequence 70 identity (50%) with hMOB1 than hMOB2 (37%), it neither interacts with nor activates 71 NDR/LATS kinases (34, 35). Its biochemical functions remain unknown. Therefore, the 72 molecular roles of hMOB3 in the context of the mammalian Hippo pathway merit further 73 investigation. 74 In the present study we have found that the previously uncharacterized hMOB3 is overexpressed 75 in GBM. Biochemically, hMOB3 directly interacts with MST1 kinase in response to apoptotic 76 stimuli and at high cell density. Functionally, hMOB3 negatively regulates MST1 cleavage 77 during etoposide-induced apoptosis and attenuates the apoptotic response. Moreover, hMOB3 is 78 required to sustain tumor cell proliferation and growth in vitro and in vivo. Taken together, our 79 study reveals that hMOB3 restricts the crosstalk between MST1 and caspases during apoptosis 80 and supports tumorigenesis in GBM suggesting hMOB3 as a potential target for GBM therapy. 81 82 Materials and Methods 83 Patients. Tissue samples of primary GBM and adjacent non-neoplastic brain were processed in 84 accordance with the guidelines of the Ethical Committee of the University Hospital of Basel. 4 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2014 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2014; DOI: 10.1158/0008-5472.CAN-13-3430 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 85 Tumors were diagnosed and graded according to the World Health Organization (WHO) 86 Classification of Tumors of the Nervous System (40). 87 Cell culture, transfection, and stimulation. HEK293 cell line was obtained from American 88 Type Culture Collection (ATCC). Glioma cell lines were described previously (41, 42). All the 89 cell lines in this study were confirmed with absence of mycoplasma contamination 90 (MycoAlertTM, Lonza) and regularly authenticated by growth and morphological observations. 91 HEK293 and glioma cell lines were maintained in Dulbecco's modified Eagle's medium 92 supplemented with 10% fetal calf serum. Transfection of HEK293 and GBM cells were carried 93 out using jetPEI (PolyPlus Transfections, Dietikon, Switzerland) and Lipofectamine 2000 94 (Invitrogen, CA, USA) according to the manufacturer's instructions, respectively. Apoptosis was 95 induced as indicated in the figure legends. Okadaic acid was purchased from Alexis 96 Biochemicals (Enzo Life Sciences, Lausen, Switzerland). Cyclohexylamine (CHX), actinomycin 97 D and etoposide were obtained from Sigma (St Louis, MO, USA). 98 Annexin V assay. Annexin V staining was performed according to the manufacturer's 99 instructions (BD Bioscience) and analyzed by FACSCalibur. The results were from three 100 independent experiments and presented as mean ± standard deviation. Statistical analysis is 101 performed in Excel with two tailed-paired-student t test. 102 Tumor Implantation: Aythymic Nude–Foxn1nu mice (Harlan, France) were maintained in 103 Specific and Opportunistic Pathogen Free (SOPF) facility with food and water ad libitum. 104 U87MG cells (8x105 in 200μl DMEM:Matrigel(1:1 ratio)) were implanted into left flanks. 105 Tumor diameters were regularly measured via caliper and tumor volumes calculated as follows: 106 Volume = d2 D π/6, where d is shorter tumor diameter and D is longer tumor diameter. All 5 Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2014 American Association
Load more

Recommended publications
  • The C9orf72-Interacting Protein Smcr8 Is a Negative Regulator of Autoimmunity and Lysosomal Exocytosis
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis Yingying Zhang,1,2,3 Aaron Burberry,1,2,3 Jin-Yuan Wang,1,2,3 Jackson Sandoe,1,2,3 Sulagna Ghosh,1,2,3 Namrata D. Udeshi,4 Tanya Svinkina,4 Daniel A. Mordes,1,2,3,5 Joanie Mok,1,2,3 Maura Charlton,1,2,3 Quan-Zhen Li,6,7 Steven A. Carr,4 and Kevin Eggan1,2,3 1Department of Stem Cell and Regenerative Biology, 2Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA; 3Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA; 4Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA; 5Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA; 6Department of Immunology, 7Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA While a mutation in C9ORF72 is the most common genetic contributor to amyotrophic lateral sclerosis (ALS), much remains to be learned concerning the function of the protein normally encoded at this locus. To elaborate further on functions for C9ORF72, we used quantitative mass spectrometry-based proteomics to identify interacting proteins in motor neurons and found that its long isoform complexes with and stabilizes SMCR8, which further enables interaction with WDR41. To study the organismal and cellular functions for this tripartite complex, we generated Smcr8 loss-of-function mutant mice and found that they developed phenotypes also observed in C9orf72 loss-of- function animals, including autoimmunity.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Porcine Interferon Complex and Co-Evolution with Increasing Viral Pressure After Domestication
    viruses Review Porcine Interferon Complex and Co-Evolution with Increasing Viral Pressure after Domestication Jordan Jennings and Yongming Sang * Department of Agricultural and Environmental Sciences, College of Agriculture, Tennessee State University, Nashville, TN 37209, USA; [email protected] * Correspondence: [email protected]; Tel.: +615-963-5183 Received: 17 May 2019; Accepted: 13 June 2019; Published: 15 June 2019 Abstract: Consisting of nearly 60 functional genes, porcine interferon (IFN)-complex represents an evolutionary surge of IFN evolution in domestic ungulate species. To compare with humans and mice, each of these species contains about 20 IFN functional genes, which are better characterized using the conventional IFN-α/β subtypes as examples. Porcine IFN-complex thus represents an optimal model for studying IFN evolution that resulted from increasing viral pressure during domestication and industrialization. We hypothesize and justify that porcine IFN-complex may extend its functionality in antiviral and immunomodulatory activity due to its superior molecular diversity. Furthermore, these unconventional IFNs could even confer some functional and signaling novelty beyond that of the well-studied IFN-α/β subtypes. Investigations into porcine IFN-complex will further our understanding of IFN biology and promote IFN-based therapeutic designs to confront swine viral diseases. Keywords: interferon; immune evolution; antiviral; porcine model 1. Introduction Interferons (IFNs) are a group of cytokines that have evolved in jawed vertebrates and bear a pivotal role in antiviral regulation as well as other biological functions [1–4]. Three types of IFNs, namely Type I, II, and III IFNs, have been defined based on their molecular signatures, interacting receptors, and signaling propensities in immune regulation [3,4].
    [Show full text]
  • 2018 Award Recipients
    AWARD RECIPIENTS 1 CREATING A BRIGHTER FUTURE FOR RHEUMATOLOGY The Rheumatology Research Foundation is committed to improving care for the more than 54 million Americans affected by arthritis or other forms of rheumatic disease. The Foundation’s extensive awards program helps patients by increasing the number of rheumatology health professionals while also funding research advancements that lead to new treatments and cures. For more than two decades, the Foundation has supported high-quality clinical and translational research as well as education and training programs. In the coming fiscal year (July 1, 2018 – June 30, 2019), the Foundation has committed to fund more than $9.4 million to rheumatology research and training. About half of those awards will support efforts to recruit and train the next generation of rheumatology professionals, which decreases patient wait times and increases access to rheumatology care. The remaining funds will be awarded to advance research projects that lead to breakthroughs in treating people with rheumatic diseases. In all, the Foundation has committed more than $161 million to fund more than 3,400 awards since 1985, making it the largest private funding source of rheumatology research and training in the United States. Congratulations to the Foundation’s latest award recipients. Their work is vital to creating a brighter future for the field of rheumatology and for the people impacted by rheumatic disease. BRYCE A. BINSTADT, MD, PHD CHAIR, SCIENTIFIC ADVISORY COUNCIL ASSOCIATE PROFESSOR OF PEDIATRICS AND A DISTINGUISHED UNIVERSITY TEACHING PROFESSOR, DIVISION OF PEDIATRIC RHEUMATOLOGY, UNIVERSITY OF MINNESOTA MEDICAL SCHOOL 2 TABLE OF CONTENTS 04 INNOVATIVE RESEARCH AWARDS 13 CAREER DEVELOPMENT RESEARCH AWARDS 14 CAREER DEVELOPMENT BRIDGE FUNDING AWARD: K BRIDGE 15 CAREER DEVELOPMENT BRIDGE FUNDING AWARD: K SUPPLEMENT 16 CAREER DEVELOPMENT BRIDGE FUNDING AWARD: R BRIDGE 18 INVESTIGATOR AWARD 21 SCIENTIST DEVELOPMENT AWARD 29 TOBÉ AND STEPHEN E.
    [Show full text]
  • IFNK (NM 020124) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC221055L4 IFNK (NM_020124) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: IFNK (NM_020124) Human Tagged ORF Clone Tag: mGFP Symbol: IFNK Synonyms: IFNT1; INFE1 Vector: pLenti-C-mGFP-P2A-Puro (PS100093) E. coli Selection: Chloramphenicol (34 ug/mL) Cell Selection: Puromycin ORF Nucleotide The ORF insert of this clone is exactly the same as(RC221055). Sequence: Restriction Sites: SgfI-MluI Cloning Scheme: ACCN: NM_020124 ORF Size: 621 bp This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 IFNK (NM_020124) Human Tagged ORF Clone – RC221055L4 OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. RefSeq: NM_020124.1 RefSeq Size: 1164 bp RefSeq ORF: 624 bp Locus ID: 56832 UniProt ID: Q9P0W0 Protein Families: Druggable Genome, Secreted Protein, Transmembrane Protein Pathways: Cytokine-cytokine receptor interaction, Jak-STAT signaling pathway, RIG-I-like receptor signaling pathway MW: 22.1 kDa Gene Summary: This gene encodes a member of the type I interferon family.
    [Show full text]
  • Genome-Scale Activation Screen Identifies a Lncrna Locus Regulating a Gene Neighbourhood Julia Joung1,2,3,4, Jesse M
    LETTER doi:10.1038/nature23451 Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood Julia Joung1,2,3,4, Jesse M. Engreitz2, Silvana Konermann2,3,4†, Omar O. Abudayyeh2,3,4,5, Vanessa K. Verdine2,3, Francois Aguet2, Jonathan S. Gootenberg2,3,4,6, Neville E. Sanjana2,3,4†, Jason B. Wright2,3,4, Charles P. Fulco2,6, Yuen-Yi Tseng2, Charles H. Yoon7, Jesse S. Boehm2, Eric S. Lander2,6,8 & Feng Zhang1,2,3,4 Mammalian genomes contain thousands of loci that transcribe long genes, one of which confers the resistance phenotype. Our screening noncoding RNAs (lncRNAs)1,2, some of which are known to carry and characterization approach provides a CRISPR toolkit with out critical roles in diverse cellular processes through a variety of which to systematically discover the functions of noncoding loci and mechanisms3–8. Although some lncRNA loci encode RNAs that elucidate their diverse roles in gene regulation and cellular function. act non-locally (in trans)5, there is emerging evidence that many We have previously used the Cas9 synergistic activation mediator lncRNA loci act locally (in cis) to regulate the expression of nearby (SAM) to screen for protein-coding genes that confer resistance to genes—for example, through functions of the lncRNA promoter, the BRAF inhibitor vemurafenib in melanoma cells9, making this an transcription, or transcript itself3,6–8. Despite their potentially ideal phenotype for screening lncRNA loci (Supplementary Note 1). important roles, it remains challenging to identify functional We designed a genome-scale single guide RNA (sgRNA) library lncRNA loci and distinguish among these and other mechanisms.
    [Show full text]
  • Regulation of Type I Interferons in Health and Autoimmune Disease
    Regulation of type I interferons in health and autoimmune disease Antonios Psarras Submitted in accordance with the requirements for the degree of Doctor of Philosophy (PhD) University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine September 2018 i Intellectual property and publication statements The candidate confirms that the work submitted is his own, except where work which has formed part of jointly-authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. Chapter 1 includes data from a jointly-authored publication: Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. Psarras A performed the review of literature, critically appraised scientific evidences of the relevant topics and led the writing of the manuscripts. Emery revised the manuscripts for important intellectual content and final approval of the manuscript. Chapter 3 includes data from two jointly-authored publications: El-Sherbiny YM*, Psarras A*, Yusof MYM, Hensor EMA, Tooze R, Doody G, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8(1):5793. *joint first author El-Sherbiny YM, Emery P, and Vital EM performed conception and design
    [Show full text]
  • Genetic Regulation of Tmem106b in the Pathogenesis of Frontotemporal Lobar Degeneration
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Genetic Regulation Of Tmem106b In The Pathogenesis Of Frontotemporal Lobar Degeneration Michael Gallagher University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Genetics Commons, Molecular Biology Commons, and the Neuroscience and Neurobiology Commons Recommended Citation Gallagher, Michael, "Genetic Regulation Of Tmem106b In The Pathogenesis Of Frontotemporal Lobar Degeneration" (2017). Publicly Accessible Penn Dissertations. 2294. https://repository.upenn.edu/edissertations/2294 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2294 For more information, please contact [email protected]. Genetic Regulation Of Tmem106b In The Pathogenesis Of Frontotemporal Lobar Degeneration Abstract Neurodegenerative diseases are an emerging global health crisis, with the projected global cost of dementia alone expected to exceed $1 trillion, or >1% of world GDP, by 2018. However, there are no disease-modifying treatments for the major neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis. Therefore, there is an urgent need for a better understanding of the pathophysiology underlying these diseases. While genome-wide association studies (GWAS) have identified ~200 genetic ariantsv that are associated with risk of developing neurodegenerative disease, the biological mechanisms underlying these associations are largely unknown. This dissertation investigates the mechanisms by which common genetic variation at TMEM106B, a GWAS-identified risk locus for FTLD, influences disease risk. First, using genetic and clinical data from thirty American and European medical centers, I demonstrate that the TMEM106B locus acts as a genetic modifier of a common Mendelian form of FTLD.
    [Show full text]
  • IFNK Monoclonal Antibody (M01), Expressed in Keratinocytes and the Gene Is Found on Clone 1B7 Chromosome 9, Adjacent to the Type I Interferon Cluster
    IFNK monoclonal antibody (M01), expressed in keratinocytes and the gene is found on clone 1B7 chromosome 9, adjacent to the type I interferon cluster. [provided by RefSeq] Catalog Number: H00056832-M01 References: Regulatory Status: For research use only (RUO) 1. High risk HPV repress constitutive interferon-kappa transcription via E6 to prevent pathogen recognition Product Description: Mouse monoclonal antibody receptor and antiviral gene expression. Reiser J, Hurst J, raised against a partial recombinant IFNK. Voges M, Kraus P, Munch P, Iftner T, Stubenrauch F. J Virol. 2011 Aug 17. [Epub ahead of print] Clone Name: 1B7 2. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Rincon-Orozco B, Immunogen: IFNK (NP_064509, 35 a.a. ~ 129 a.a) Halec G, Rosenberger S, Muschik D, Nindl I, Bachmann partial recombinant protein with GST tag. MW of the A, Ritter TM, Dondog B, Ly R, Bosch FX, Zawatzky R, GST tag alone is 26 KDa. Rosl F. Cancer Res. 2009 Nov 15;69(22):8718-25. Epub 2009 Nov 3. Sequence: VHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQE FLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKE RHLKQIQIGLDQQAEYLNQCL Host: Mouse Reactivity: Human Applications: ELISA, WB-Re (See our web site product page for detailed applications information) Protocols: See our web site at http://www.abnova.com/support/protocols.asp or product page for detailed protocols Isotype: IgG2a Kappa Storage Buffer: In 1x PBS, pH 7.4 Storage Instruction: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. Entrez GeneID: 56832 Gene Symbol: IFNK Gene Alias: RP11-27J8.1 Gene Summary: This gene encodes a member of the type I interferon family.
    [Show full text]
  • Unique Responses of the Avian Macrophage to Different Species of Eimeria Rami A
    Molecular Immunology 44 (2007) 558–566 Unique responses of the avian macrophage to different species of Eimeria Rami A. Dalloul a,1, Travis W. Bliss b,1, Yeong-Ho Hong a, Imed Ben-Chouikha a, Dong Woon Park a, Calvin L. Keeler b, Hyun S. Lillehoj a,∗ a Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, USDA Agricultural Research Service, Bldg. 1040, BARC-East, Beltsville, MD 20705, United States b Department of Animal and Food Sciences, College of Agriculture and Natural Resources, University of Delaware, Newark, DE 19716, United States Received 6 January 2006; received in revised form 7 February 2006; accepted 9 February 2006 Available online 24 March 2006 Abstract Coccidiosis is recognized as the major parasitic disease of poultry and is caused by the apicomplexan protozoa Eimeria. Increasing evidence shows the complexity of the host immune response to Eimeria and microarray technology presents a powerful tool for the study of such an intricate biological process. Using an avian macrophage microarray containing 4906 unique gene elements, we identified important host genes whose expression changed following infection of macrophages with sporozoites of Eimeria tenella (ET), Eimeria acervulina (EA), and Eimeria maxima (EM). This approach enabled us to identify a common core of 25 genetic elements whose transcriptional expression is induced or repressed by exposure to Eimeria sporozoites and to identify additional transcription patterns unique to each individual Eimeria species. Besides inducing the expression of IL-1␤, IL-6, and IL-18 and repressing the expression of IL-16, Eimeria treated macrophages were commonly found to induce the expression of the CCL chemokine family members macrophage inflammatory protein (MIP)-1␤ (CCLi1), K203 (CCLi3), and ah221 (CCLi7).
    [Show full text]
  • Complexes of Oligoribonucleotides with D-Mannitol Modulate the Innate Immune Response to Influenza a Virus H1N1
    pharmaceuticals Article Complexes of Oligoribonucleotides with D-Mannitol Modulate the Innate Immune Response to Influenza A Virus H1N1 (A/FM/1/47) In Vivo Nataliia Melnichuk 1 ID , Vladimir Kashuba 1,2, Svitlana Rybalko 3 and Zenoviy Tkachuk 1,* 1 Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, 03680 Kyiv, Ukraine; [email protected] (N.M.); [email protected] (V.K.) 2 Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, S-17177 Stockholm, Sweden 3 Gromashevsky L. V. Institute of Epidemiology and Infectious Diseases, NAMSU, 5 Amosov str., 03038 Kyiv, Ukraine; [email protected] * Correspondence: [email protected]; Tel.: +38-067-728-0418 Received: 19 June 2018; Accepted: 18 July 2018; Published: 22 July 2018 Abstract: Rapid replication of the influenza A virus and lung tissue damage caused by exaggerated pro-inflammatory host immune responses lead to numerous deaths. Therefore, novel therapeutic agents that have anti-influenza activities and attenuate excessive pro-inflammatory responses that are induced by an influenza virus infection are needed. Oligoribonucleotides-D-mannitol (ORNs-D-M) complexes possess both antiviral and anti-inflammatory activities. The current research was aimed at studying the ORNs-D-M effects on expression of innate immune genes in mice lungs during an influenza virus infection. Expression of genes was determined by RT-qPCR and Western blot assays. In the present studies, we found that the ORNs-D-M reduced the influenza-induced up-expression of Toll-like receptors (TLRs) (tlr3, tlr7, tlr8), nuclear factor NF-kB (nfkbia, nfnb1), cytokines (ifn#, ifnk, ifna2, ifnb1, ifng, il6, il1b, il12a, tnf ), chemokines (ccl3, ccl4, ccl5, cxcl9, cxcl10, cxcl11), interferon-stimulated genes (ISGs) (oas1a, oas2, oas3, mx1), and pro-oxidation (nos2, xdh) genes.
    [Show full text]
  • Gene Polymorphisms That Can Predict Response to Anti-TNF Therapy in Patients with Psoriasis and Related Autoimmune Diseases
    The Pharmacogenomics Journal (2013) 13, 297–305 & 2013 Macmillan Publishers Limited All rights reserved 1470-269X/13 www.nature.com/tpj REVIEW Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases R Prieto-Pe´ rez1, T Cabaleiro1, E Daude´n2 and F Abad-Santos1 Psoriasis (Ps) is a chronic inflammatory disease with an important genetic component. It shares pathophysiological mechanisms with other autoimmune diseases such as psoriatic arthritis (PsA), rheumatoid arthritis (RA) and Crohn’s disease (CD). These conditions can be treated using biological drugs such as infliximab, adalimumab and etanercept, which selectively block the proinflammatory cytokine tumor necrosis factor (TNF)-a. Although these agents have greatly improved the prognosis of Ps, PsA, RA and CD, they do not cure the disease and are expensive; in addition, significant proportions of patients do not respond or develop serious adverse effects. Therefore, it is important to investigate biomarkers, such as gene polymorphisms, that can predict which patients will respond best to a specific drug. Some polymorphisms in genes TNF, TNF receptor superfamily 1B (TNFR1B) and TNFa-induced protein 3 gene (TNFAIP3) have been associated with response to anti-TNF therapy in patients with Ps. The present article reviews other polymorphisms that could also play a role in prediction of response to these treatments. The Pharmacogenomics Journal (2013) 13, 297–305; doi:10.1038/tpj.2012.53; published online 22 January 2013 Keywords: gene polymorphisms; psoriasis; etanercept; adalimumab; infliximab INTRODUCTION Medicines Agency, an 8-to-12-weeks study is generally sufficient 11,12 Psoriasis (Ps) is a chronic inflammatory disease with a multi- to show short-term efficacy.
    [Show full text]